Clinical trials: Sleep Disorders, Circadian Rhythm
Excessive Sleepiness, Shift-work Disorder
Studying Solriamfetol Modulation of TAAR-1, Dopamine, and Norepinephrine in Shift Work Disorder (SUSTAIN)
SUSTAIN (Studying Solriamfetol Modulation of TAAR-1, Dopamine, and Norepinephrine in Shift Work Disorder) is a Phase 3, multi-center, randomized, double-blind, placebo-controlled, parallel- group trial to assess the efficacy and…
- Trial name
- NCT06568367
- Testing
- Solriamfetol 150 mg, Solriamfetol 300 mg
- Where
- 49 sites in United States, Canada
- Volunteers
- 520 people
- Sponsor
- Axsome Therapeutics, Inc.
Jet Lag Disorder, Jet Lag
A Study on the Effectiveness of a Dietary Supplement FitoAvia for Jet Lag
Purpose of the study: Evaluation of the effects of dietary supplement Fitoavia in people with dyssynchrony Objectives of the study: 1. Assessment of the condition of patients with jet lag of 4 hours or more 2.
- Conditions
- Jet Lag Disorder, Jet Lag, Jet Lag Type Insomnia, Cognition Improvement
- Trial name
- NCT07695870
- Testing
- Fitoavia, Questionnaire and Physical Exam, cognition tests
- Where
- Russia
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- MiraxBioPharma
Irregular Sleep Wake Rhythm Disorder
A Study to Determine the Signs and Symptoms That Impact Daily Life of Participants With Irregular Sleep-Wake Rhythm Disorder
The primary purpose of this study is to determine the signs and symptoms of irregular sleep-wake rhythm disorder (ISWRD) that are important to patients and caregivers of patients with Alzheimer's disease dementia (AD-D), AD-D…
- Trial name
- NCT04300569
- Testing
- Non-interventional
- Where
- 6 sites in United States
- Volunteers
- 37 people
- Sponsor
- Eisai Inc.
Sleep Wake Disorders, Sleep Disorders, Circadian Rhythm
Evaluating the Effects of Tasimelteon vs. Placebo in Delayed Sleep-Wake Phase Disorder (DSWPD)
This is a multicenter, double-blind, randomized study to evaluate the efficacy and safety of a daily single oral dose of tasimelteon and matching placebo in male and female participants with DSWPD.
- Conditions
- Sleep Wake Disorders, Sleep Disorders, Circadian Rhythm, Chronobiology Disorders
- Trial name
- NCT04652882
- Testing
- Tasimelteon
- Where
- 17 sites in United States, Austria and 1 more
- Volunteers
- 43 people
- Sponsor
- Vanda Pharmaceuticals
Insomnia, Sleep
Vestibular Nerve Stimulation to Improve Sleep
A randomized, double blind sham controlled clinical trial to evaluate the efficacy of vestibular nerve stimulation (VeNS) compared to a sham control a as a means of improving sleep as measured by ISI scores and EEG recordings The…
- Conditions
- Insomnia, Sleep, Sleep Disorders, Circadian Rhythm
- Trial name
- NCT04219566
- Testing
- VeNS
- Where
- India
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Neurovalens Ltd.
Chronic Insomnia, Sleep Deprivation
Evaluating the Efficacy and Safety of PROSOMNIA Sleep Therapy™ in Patients With Sleep Deprivation and Chronic Insomnia
This clinical trial aims to evaluate the safety and efficacy of PROSOMNIA Sleep Therapy (PSTx) for individuals suffering from chronic insomnia, sleep deprivation, and REM sleep disorders.
- Conditions
- Chronic Insomnia, Sleep Deprivation, REM Behavior Disorder, REM Sleep Behavior Disorder
- Trial name
- PSHW (NCT06644573)
- Testing
- PROSOMNIA Sleep Therapy™ (PSTx), Anesthesia-Induced Sleep Therapy, Diprivan (propofol), Astra-Zeneca
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Nyree Penn
Sleep-wake Disorder in Blind Individuals
Patient Registry of Blind Subjects With Sleep-related Problems
Non-24-hour sleep-wake disorder (Non-24) is a condition experienced primarily by totally blind individuals that results in abnormal night sleep patterns and chronic daytime sleepiness.
- Trial name
- NCT01195558
- Testing
- Data collection on blindness and sleep problems
- Where
- United States
- Volunteers
- 10,000 people
- Sponsor
- Vanda Pharmaceuticals
Sleep Disorder
Safety and Efficacy of Ramelteon in Healthy Subjects
The purpose of this study is to determine the phase-advance in circadian rhythms in healthy adults subjects taking ramelteon, once daily (QD).
- Trial name
- NCT00671190
- Testing
- Ramelteon
- Where
- 13 sites in United States
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- Takeda
Non-24-Hour Sleep-Wake Disorder
Efficacy and Safety of Tasimelteon Compared With Placebo in Totally Blind Subjects With Non-24-Hour Sleep-Wake Disorder
The purpose of this study is to evaluate the efficacy and safety of a six month double-mask treatment of tasimelteon or placebo in male and female subjects with Non-24-Hour Sleep-Wake Disorder
- Trial name
- NCT01163032
- Testing
- tasimelteon
- Where
- 28 sites in United States, Germany
- Volunteers
- 136 people
- Sponsor
- Vanda Pharmaceuticals
Sleep Apnea Syndromes, Insomnia
Evaluation of the Reliability and Validity of a Diagnostic Sleep Disorders Questionnaire
The study aims to develop and test a user-friendly, accessible approach to sleep assessment which can function as an initial "triage" of targeted sleep conditions, such as insomnia, insufficient sleep syndrome, sleep apnea…
- Conditions
- Sleep Apnea Syndromes, Insomnia, Insufficient Sleep Syndrome, Circadian Rhythm Disorders
- Trial name
- NCT03468400
- Where
- 2 sites in United States, Israel
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- Dayzz Live Well Ltd.
Irregular Sleep-Wake Rhythm Disorder
Study of Lemborexant for Irregular Sleep-Wake Rhythm Disorder and Mild to Moderate Alzheimer's Disease Dementia
This study will be conducted to determine the dose response of lemborexant (LEM) on the change from baseline in actigraphy-derived sleep-related parameters, wake-related parameters, and circadian-rhythm related parameters.
- Trial name
- NCT03001557
- Testing
- Lemborexant 2.5 mg, Lemborexant 5 mg, Lemborexant 10 mg
- Where
- 48 sites in United States, Japan and 1 more
- Volunteers
- 63 people
- Sponsor
- Eisai Inc.
Excessive Sleepiness, Shift Work Sleep Disorder
Safety/Efficacy Study With Armodafinil (CEP-10953) in Treatment of Excessive Sleepiness Associated With Chronic SWSD
The primary objective of this study is to determine whether treatment with Armodafinil (CEP-10953) is more effective than placebo treatment for patients with excessive sleepiness associated with chronic shift work sleep disorder…
- Trial name
- NCT00080288
- Testing
- Armodafinil 150 mg/day
- Volunteers
- 254 people
- Sponsor
- Cephalon